Skip To Content
Volunteer Advocate


All media inquiries can be directed to or by calling 1-800-378-2233.

Cystic Fibrosis Canada Board of Directors Announces Resignation of CEO Norma Beauchamp
August 24, 2017

TORONTO (August 24, 2017) — Cystic Fibrosis Canada’s (CF Canada) Board of Directors has announced the resignation of Chief Executive Officer (CEO) Norma Beauchamp. Norma’s last day with the organization will be November 3, 2017.

“Norma has been a tireless advocate and leader for the cystic fibrosis community and for the work our organization does to support those living with CF,” said Mitch LePage, Chairman of the CF Canada Board of Directors. “The Board is grateful for her dedication and effort that has helped Cystic Fibrosis Canada make continued progress, and we are excited to see what this next chapter brings for all of us working to end CF.”

Read More
New Data on Triple Combination Therapies Positive News for Canadians with CF
July 21, 2017

Cystic Fibrosis Canada is excited to hear that data from early stage clinical trials led by Vertex Pharmaceuticals Inc. resulted in significantly improved lung function in people with one F508del mutation and one minimal function mutation (F508del/Min).

The triple combination therapy uses a combination of ivacaftor (known as Kalydeco), Vertex’s new product tezacaftor, and a third compound to tackle the mutation of the CF gene, which is the underlying cause of cystic fibrosis (CF). This is the first data to demonstrate the potential to treat the underlying cause of CF in people with F508del/Min mutations, a severe and difficult-to-treat type of the disease.

Read More
Cystic Fibrosis Canada Celebrates Newborn Screening for CF in Quebec
June 8, 2017

June 8, 2017 (Quebec) – CF Canada is overjoyed with today's announcement by Quebec’s Ministry of Health and Social Services that a screening program for CF in newborns will finally be implemented.

Read More
Quebecers with cystic fibrosis denied access to medication that substantially improves their life
June 2, 2017

June 2, 2017 (Montréal, QC) ? As Cystic Fibrosis Awareness Month comes to an end, Cystic Fibrosis Canada is extremely disappointed to learn that those living with cystic fibrosis (CF) in Québec will not have access to lumacaftor/ivacaftor (ORKAMBI) – a life-changing medication – through the list of medications reimbursed by the Régie d’assurance maladie du Québec (RAMQ), because of the recent recommendation issued by the Institut national d’excellence en santé et en services sociaux (INESSS).

Read More
CF Canada fights for Canadians living with cystic fibrosis
May 2, 2017

May is cystic fibrosis (CF) Awareness Month, and Cystic Fibrosis Canada (CF Canada) is launching a campaign to ensure Canadians are aware of the significant challenges around access to drugs many with CF are currently facing. As research breakthroughs and new drugs that can vastly improve the quality and length of life for people with CF become available, it is essential those who can benefit gain access to these advances in health care.

Read More
Cystic Fibrosis Canada Applauds Health Canada’s Approval of ORKAMBI™
April 20, 2017

Health Canada’s approval of ORKAMBITM for children with cystic fibrosis (CF) aged 6 to 11 years means that they could stand a better chance at living a longer, healthier life. Approximately 267 Canadian children with CF could benefit from access to this breakthrough treatment.

Read More
BC residents with cystic fibrosis will be denied life-changing drug through Pharmacare
March 22, 2017

Cystic Fibrosis Canada is extremely disappointed that people with cystic fibrosis (CF) in British Columbia will not be able to access lumacaftor/ivacaftor (ORKAMBI™) - a potentially life-changing drug - through the BC Pharmacare program, due to a recent decision to “close the books” on ORKAMBI™.

Read More
Cystic Fibrosis Canada disappointed that access to ORKAMBI™ is delayed
July 19, 2016

Cystic Fibrosis Canada is disappointed that people with cystic fibrosis (CF) in Canada are going to have wait even longer to gain access to ORKAMBI™, a potentially life-changing drug.

Read More
Cystic Fibrosis Canada partners with Party City Canada
March 17, 2016

Cystic Fibrosis Canada is thrilled to welcome Party City Canada as a new national partner. Party City has 50 stores in Canada and operates in every province excluding, PEI, Quebec and Manitoba. Cystic Fibrosis Canada is one of five non-profit organizations to benefit this year from the Party City CARES cause marketing campaign.

Read More
Laurent Pharmaceuticals to receive investment from Cystic Fibrosis Canada
March 17, 2016

MONTREAL, March 17th, 2016 /CNW Telbec/ - Laurent Pharmaceuticals Inc. announced today the closing of a financing round led by Cystic Fibrosis Canada. Existing investors Aligo Innovation LP (previously MSBi Valorisation) and members of Anges Quebec, as well as other existing and new private investors, also participated in the round.

This investment will allow the preparation of the upcoming Phase 2 clinical trial with LAU-7b in cystic fibrosis (CF) patients, planned to start later this year in Canada and United States. LAU-7b is a once-a-day oral drug addressing the persistent and unresolved inflammation, a leading cause of lung tissue destruction in CF.

Read More